Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)

Nicolas Menjot De Champfleur, Jeffrey L. Saver, Mayank Goyal, Reza Jahan, Hans Christoph Diener, Alain Bonafe, Elad I. Levy, Vitor M. Pereira, Christophe Cognard, Dileep R Yavagal, Gregory W. Albers

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Purpose-The majority of patients enrolled in SWIFT PRIME trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) had computed tomographic perfusion (CTP) imaging before randomization; 34 patients were randomized after magnetic resonance imaging (MRI). Methods-Patients with middle cerebral artery and distal carotid occlusions were randomized to treatment with tPA (tissue-Type plasminogen activator) alone or tPA+stentriever thrombectomy. The primary outcome was the distribution of the modified Rankin Scale score at 90 days. Patients with the target mismatch profile for enrollment were identified on MRI and CTP. Results-MRI selection was performed in 34 patients; CTP in 139 patients. Baseline National Institutes of Health Stroke Scale score was 17 in both groups. Target mismatch profile was present in 95% (MRI) versus 83% (CTP). A higher percentage of the MRI group was transferred from an outside hospital (P=0.02), and therefore, the time from stroke onset to randomization was longer in the MRI group (P=0.003). Time from emergency room arrival to randomization did not differ in CTP versus MRI-selected patients. Baseline ischemic core volumes were similar in both groups. Reperfusion rates (>90%/TICI [Thrombolysis in Cerebral Infarction] score 3) did not differ in the stentriever-Treated patients in the MRI versus CTP groups. The primary efficacy analysis (90-day MRS score) demonstrated a statistically significant benefit in both subgroups (MRI, P=0.02; CTP, P=0.01). Infarct growth was reduced in the stentriever-Treated group in both MRI and CTP groups. Conclusions-Time to randomization was significantly longer in MRI-selected patients; however, site arrival to randomization times were not prolonged, and the benefits of endovascular therapy were similar. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01657461.

Original languageEnglish (US)
Pages (from-to)1560-1566
Number of pages7
JournalStroke
Volume48
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Thrombectomy
Stents
Perfusion
Stroke
Magnetic Resonance Imaging
Random Allocation
Therapeutics
Tissue Plasminogen Activator
Perfusion Imaging
Magnetic Resonance Angiography
Cerebral Infarction
Middle Cerebral Artery
National Institutes of Health (U.S.)
Reperfusion
Hospital Emergency Service
Clinical Trials

Keywords

  • brain ischemia
  • cerebrovascular disorders
  • magnetic resonance imaging
  • patient selection
  • stroke
  • thrombectomy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). / Menjot De Champfleur, Nicolas; Saver, Jeffrey L.; Goyal, Mayank; Jahan, Reza; Diener, Hans Christoph; Bonafe, Alain; Levy, Elad I.; Pereira, Vitor M.; Cognard, Christophe; Yavagal, Dileep R; Albers, Gregory W.

In: Stroke, Vol. 48, No. 6, 01.06.2017, p. 1560-1566.

Research output: Contribution to journalArticle

Menjot De Champfleur, Nicolas ; Saver, Jeffrey L. ; Goyal, Mayank ; Jahan, Reza ; Diener, Hans Christoph ; Bonafe, Alain ; Levy, Elad I. ; Pereira, Vitor M. ; Cognard, Christophe ; Yavagal, Dileep R ; Albers, Gregory W. / Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). In: Stroke. 2017 ; Vol. 48, No. 6. pp. 1560-1566.
@article{16b38c0c3a8f4c2383c8a0bef0f6d6d0,
title = "Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)",
abstract = "Background and Purpose-The majority of patients enrolled in SWIFT PRIME trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) had computed tomographic perfusion (CTP) imaging before randomization; 34 patients were randomized after magnetic resonance imaging (MRI). Methods-Patients with middle cerebral artery and distal carotid occlusions were randomized to treatment with tPA (tissue-Type plasminogen activator) alone or tPA+stentriever thrombectomy. The primary outcome was the distribution of the modified Rankin Scale score at 90 days. Patients with the target mismatch profile for enrollment were identified on MRI and CTP. Results-MRI selection was performed in 34 patients; CTP in 139 patients. Baseline National Institutes of Health Stroke Scale score was 17 in both groups. Target mismatch profile was present in 95{\%} (MRI) versus 83{\%} (CTP). A higher percentage of the MRI group was transferred from an outside hospital (P=0.02), and therefore, the time from stroke onset to randomization was longer in the MRI group (P=0.003). Time from emergency room arrival to randomization did not differ in CTP versus MRI-selected patients. Baseline ischemic core volumes were similar in both groups. Reperfusion rates (>90{\%}/TICI [Thrombolysis in Cerebral Infarction] score 3) did not differ in the stentriever-Treated patients in the MRI versus CTP groups. The primary efficacy analysis (90-day MRS score) demonstrated a statistically significant benefit in both subgroups (MRI, P=0.02; CTP, P=0.01). Infarct growth was reduced in the stentriever-Treated group in both MRI and CTP groups. Conclusions-Time to randomization was significantly longer in MRI-selected patients; however, site arrival to randomization times were not prolonged, and the benefits of endovascular therapy were similar. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01657461.",
keywords = "brain ischemia, cerebrovascular disorders, magnetic resonance imaging, patient selection, stroke, thrombectomy",
author = "{Menjot De Champfleur}, Nicolas and Saver, {Jeffrey L.} and Mayank Goyal and Reza Jahan and Diener, {Hans Christoph} and Alain Bonafe and Levy, {Elad I.} and Pereira, {Vitor M.} and Christophe Cognard and Yavagal, {Dileep R} and Albers, {Gregory W.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1161/STROKEAHA.117.016669",
language = "English (US)",
volume = "48",
pages = "1560--1566",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Efficacy of Stent-Retriever Thrombectomy in Magnetic Resonance Imaging Versus Computed Tomographic Perfusion-Selected Patients in SWIFT PRIME Trial (Solitaire FR with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke)

AU - Menjot De Champfleur, Nicolas

AU - Saver, Jeffrey L.

AU - Goyal, Mayank

AU - Jahan, Reza

AU - Diener, Hans Christoph

AU - Bonafe, Alain

AU - Levy, Elad I.

AU - Pereira, Vitor M.

AU - Cognard, Christophe

AU - Yavagal, Dileep R

AU - Albers, Gregory W.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background and Purpose-The majority of patients enrolled in SWIFT PRIME trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) had computed tomographic perfusion (CTP) imaging before randomization; 34 patients were randomized after magnetic resonance imaging (MRI). Methods-Patients with middle cerebral artery and distal carotid occlusions were randomized to treatment with tPA (tissue-Type plasminogen activator) alone or tPA+stentriever thrombectomy. The primary outcome was the distribution of the modified Rankin Scale score at 90 days. Patients with the target mismatch profile for enrollment were identified on MRI and CTP. Results-MRI selection was performed in 34 patients; CTP in 139 patients. Baseline National Institutes of Health Stroke Scale score was 17 in both groups. Target mismatch profile was present in 95% (MRI) versus 83% (CTP). A higher percentage of the MRI group was transferred from an outside hospital (P=0.02), and therefore, the time from stroke onset to randomization was longer in the MRI group (P=0.003). Time from emergency room arrival to randomization did not differ in CTP versus MRI-selected patients. Baseline ischemic core volumes were similar in both groups. Reperfusion rates (>90%/TICI [Thrombolysis in Cerebral Infarction] score 3) did not differ in the stentriever-Treated patients in the MRI versus CTP groups. The primary efficacy analysis (90-day MRS score) demonstrated a statistically significant benefit in both subgroups (MRI, P=0.02; CTP, P=0.01). Infarct growth was reduced in the stentriever-Treated group in both MRI and CTP groups. Conclusions-Time to randomization was significantly longer in MRI-selected patients; however, site arrival to randomization times were not prolonged, and the benefits of endovascular therapy were similar. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01657461.

AB - Background and Purpose-The majority of patients enrolled in SWIFT PRIME trial (Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) had computed tomographic perfusion (CTP) imaging before randomization; 34 patients were randomized after magnetic resonance imaging (MRI). Methods-Patients with middle cerebral artery and distal carotid occlusions were randomized to treatment with tPA (tissue-Type plasminogen activator) alone or tPA+stentriever thrombectomy. The primary outcome was the distribution of the modified Rankin Scale score at 90 days. Patients with the target mismatch profile for enrollment were identified on MRI and CTP. Results-MRI selection was performed in 34 patients; CTP in 139 patients. Baseline National Institutes of Health Stroke Scale score was 17 in both groups. Target mismatch profile was present in 95% (MRI) versus 83% (CTP). A higher percentage of the MRI group was transferred from an outside hospital (P=0.02), and therefore, the time from stroke onset to randomization was longer in the MRI group (P=0.003). Time from emergency room arrival to randomization did not differ in CTP versus MRI-selected patients. Baseline ischemic core volumes were similar in both groups. Reperfusion rates (>90%/TICI [Thrombolysis in Cerebral Infarction] score 3) did not differ in the stentriever-Treated patients in the MRI versus CTP groups. The primary efficacy analysis (90-day MRS score) demonstrated a statistically significant benefit in both subgroups (MRI, P=0.02; CTP, P=0.01). Infarct growth was reduced in the stentriever-Treated group in both MRI and CTP groups. Conclusions-Time to randomization was significantly longer in MRI-selected patients; however, site arrival to randomization times were not prolonged, and the benefits of endovascular therapy were similar. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01657461.

KW - brain ischemia

KW - cerebrovascular disorders

KW - magnetic resonance imaging

KW - patient selection

KW - stroke

KW - thrombectomy

UR - http://www.scopus.com/inward/record.url?scp=85019564060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019564060&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.117.016669

DO - 10.1161/STROKEAHA.117.016669

M3 - Article

C2 - 28465460

AN - SCOPUS:85019564060

VL - 48

SP - 1560

EP - 1566

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -